Saturday, April 20, 2024 | Baltimore, MD
Baltimore, MD

Rockville biotech RegenxBio launches clinical trial in muscular dystrophy

January 25, 2023

Rockville’s RegenxBio Inc., which is developing treatments for retinal and neurodegenerative diseases, has launched another clinical trial in a bid to get multiple products to market in the next few years. The clinical-stage biotech said Monday it has started a phase 1/2 trial of a gene therapy candidate for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness and atrophy. The study, now underway and recruiting patients, aims to evaluate the safety, tolerability and efficacy of the company’s one-time experimental treatment, called RGX-202.

Article Source: Baltimore Business Journal

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.